Therapeutic live vaccines as a potential anticancer strategy

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1733-1743

  Bolhassani, Azam ^a   Zahedifard, Farnaz ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

bacterial vector; cancer; live vaccine; parasite vector; viral vector

Indexed keywords

ADXS 31 164; CVD 915; INTERLEUKIN 12; LIVE VACCINE; NEWCASTLE DISEASE PARAMYXOVIRUS VACCINE; SALMONELLOSIS VACCINE; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG; VNP 2009; WART VIRUS VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BACTERIAL STRAIN; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COCCIDIOSIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIGESTIVE SYSTEM TUMOR; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; GENE DIRECTED ENZYME PRODRUG THERAPY; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; LACTOCOCCUS LACTIS; LEISHMANIA TARENTOLAE; LISTERIA MONOCYTOGENES; MELANOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; TOXOPLASMA GONDII; TRYPANOSOMA CRUZI; UTERINE CERVIX CANCER;

CANCER VACCINES; HUMANS; NEOPLASMS; VACCINES, ATTENUATED;

EID: 84865323908     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27640     Document Type: Review

References (127)

1. Rosenberg SA, yang JC, Restifo NP,. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15. (Pubitemid 39273730)
2. Marincola FM, Wang E, Herlyn M, et al. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 2003; 24: 335-42.
3. Wilson M, Seymour R, Henderson B,. Bacterial perturbation of cytokine networks. Infect Immun 1998; 66: 2401-9. (Pubitemid 28261731)
4. Shahabi V, Maciag PC, Rivera S, et al. Live attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010; 1: 235-43.
5. Lauer P, Chow MY, Loessner MJ, et al. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol 2002; 184: 4177-86. (Pubitemid 34774298)
6. Verch T, Pan ZK, Paterson Y,. Listeria monocytogenes based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 2004; 72: 6418-25. (Pubitemid 39425422)
7. Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23: 377-82.
8. Zou J, Huang XX, Yin GW, et al. Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts. Parasit Vectors 2011; 4: 168.
9. Breton M, Tremblay MJ, Ouellette M, et al. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005; 73: 6372-82. (Pubitemid 41368798)
10. Breton M, Zhao C, Ouellette M, et al. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol 2007; 88: 217-25. (Pubitemid 46085132)
11. Mizbani A, Taheri T, Zahedifard F, et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 2009; 28: 53-62.
12. Coley WB,. The treatment of inoperable malignant tumor with the toxins of erysipelas and Bacillus prodigiosus. Trans Am Surg Assoc 1894; 12: 183-96.
13. Coley WB,. The Treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 1910; 3: 1-48.
14. Tsung K, Norton JA,. Lessons from Coley's toxin. Surg Oncol 2006; 15: 25-8. (Pubitemid 44293389)
15. Jain RK, Forbes NS,. Can engineered bacteria help control cancer? Proc Natl Acad Sci USA 2001; 98: 14748-50. (Pubitemid 34013912)
16. Gardlik R, Fruehauf JH,. Bacterial vectors and delivery systems in cancer therapy. IDrugs 2010; 13: 701-6.
17. Lee CH, Wu CL, Shiau AL,. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382-93.
18. Lee CH, Wu CL, Shiau AL,. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005; 12: 175-84.
19. Bhaumik S,. Advances in imaging gene-directed enzyme prodrug therapy. Curr Pharm Biotechnol 2011; 12: 497-507.
20. Morris JC, Ramsey WJ, Wildner O, et al. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 2000; 11: 487-503. (Pubitemid 30101958)
21. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985-1001. (Pubitemid 27270161)
22. Patel P, Young JG, Mautner V, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954. Mol Ther 2009; 17: 1292-9.
23. Crump JA, Luby SP, Mintz ED,. The global burden of typhoid fever. Bull World Health Organ 2004; 82: 346-53. (Pubitemid 38715071)
24. Carter PB, Collins FM,. The route of enteric infection in normal mice. J Exp Med 1974; 139: 1189-203.
25. Jones BD, Falkow S,. Salmonellosis: host immune responses and bacterial virulence determinants. Annu Rev Immunol 1996; 14: 533-61. (Pubitemid 26130194)
26. Dunlap NE, Benjamin WH, Jr, McCall RD, Jr, et al. A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog 1991; 10: 297-310.
27. Richter-Dahlfors A, Buchan AM, Finlay BB,. Murine salmonellosis studied by confocal microscopy: Salmonella typhimurium resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes in vivo. J Exp Med 1997; 186: 569-80. (Pubitemid 27360801)
28. Fields PI, Swanson RV, Haidaris CG, et al. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci USA 1986; 83: 5189-93. (Pubitemid 16051340)
29. Germanier R, Furer E,. Isolation and characterization of galE mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J Infect Dis 1975; 131: 553-8.
30. Pawelek JM, Low KB, Bermudes D,. Tumor-targeted Salmonella as a novel anti-cancer vector. Cancer Res 1997; 57: 4537-44. (Pubitemid 27441058)
31. Rosenberg SA, Spiess PJ,., Kleiner DE,. Anti-tumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-25. (Pubitemid 34533311)
32. Agorio C, Schreiber F, Sheppard M, et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9: 416-23. (Pubitemid 46796587)
33. Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, et al. Attenuated bacteria as effectors in cancer immunotherapy. Ann NY Acad Sci 2008; 1138: 351-7.
34. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007; 14: 1285-95. (Pubitemid 350012970)
35. Baillie LW, Rodriguez AL, Moore S, et al. Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine 2008; 26: 6083-91.
36. Bumann D, Hueck C, Aebischer T, et al. Recombinant live Salmonella spp for human vaccination against heterologous pathogens. FEMS Immunol Med Microbiol 2000; 27: 357-64. (Pubitemid 30155831)
37. DiPetrillo MD, Tibbetts T, Kleanthous H, et al. Safety and immunogenicity of phoP/ phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-59. (Pubitemid 29462601)
38. Echchannaoui H, Bianchi M, Baud D, et al. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun 2008; 76: 1940-51. (Pubitemid 351656127)
39. Fensterle J, Bergmann B, Yone CL, et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther 2008; 15: 85-93.
40. Fest S, Huebener N, Bleeke M, et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 2009; 125: 104-14.
41. Fest S, Huebener N, Weixler S, et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 2006; 66: 10567-75. (Pubitemid 44799780)
42. Huebener N, Fest S, Strandsby A, et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 2008; 7: 2241-51.
43. Huebener N, Lange B, Lemmel C, et al. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett 2003; 197: 211-7. (Pubitemid 36860013)
44. Xiang R, Luo Y, Niethammer AG, et al. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008; 222: 117-28. (Pubitemid 351430375)
45. Loeffler M, Le'Negrate G, Krajewska M, et al. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother 2009; 58: 769-75.
46. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-34. (Pubitemid 26030991)
47. Seon BK, Matsuno F, Haruta Y, et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3: 1031-44. (Pubitemid 27319748)
48. Ruan Z, Yang Z, Wang Y, et al. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother 2009; 32: 486-91.
49. Chorobik P, Marcinkiewicz J,. Therapeutic vaccines based on genetically modified Salmonella: a novel strategy in cancer immunotherapy. Pol Arch Med Wewn 2011; 121: 461-7.
50. Jia LJ, Wei DP, Sun QM, et al. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 2007; 98: 1107-1112.
51. Bereta M, Hayhurst A, Gajda M, et al. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine 2007; 25: 4183-92. (Pubitemid 46646963)
52. Wang JY, Pasetti MF, Noriega FR, et al. Construction, genotypic and phenotypic characterization and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun 2001; 69: 4734-41. (Pubitemid 32674450)
53. Vendrell A, Gravisaco MJ, Pasetti MF, et al. A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. Vaccine 2011; 29: 728-36.
54. Wilson JW, Nickerson CA,. Cloning of a functional Salmonella SPI-1 type III secretion system and development of a method to create mutations and epitope fusions in the cloned genes. J Biotechnol 2006; 122: 147-60.
55. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006; 116: 1946-54. (Pubitemid 44033318)
56. Panthel K, Meinel KM, Sevil Domenech VE, et al. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol 2008; 298: 99-103. (Pubitemid 350216546)
57. Kaufmann SH, Hess J,. Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development. Immunol Lett 1999; 65: 81-4. (Pubitemid 29074504)
58. Meng JZ, Dong YJ, Huang H, et al. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses. Clin Vaccine Immunol 2010; 17: 889-94.
59. Gaillard JL, Berche P, Mounier J, et al. In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocyte-like cell line Caco-2. Infect Immun 1987; 55: 2822-9. (Pubitemid 17154530)
60. Tilney LG, Portnoy DA,. Actin filaments and the growth, movement and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol 1989; 109: 1597-608.
61. Berche P, Gaillard JL, Geoffroy C, et al. T cell recognition of listeriolysin O is induced during infection with Listeria monocytogenes. J Immunol 1987; 139: 3813-21. (Pubitemid 18013662)
62. Portnoy DA, Schreiber RD, Connelly P, et al. Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med 1989; 170: 2141-6. (Pubitemid 20010091)
63. Weiskirch LM, Pan ZK, Paterson Y,. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms. Clin Immunol 2001; 98: 346-57.
64. Ikonomidis G, Paterson Y, Kos FJ, et al. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med 1994; 180: 2209-18. (Pubitemid 24351602)
65. Seavey MM, Maciag PC, Al-Rawi N, et al. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol 2009; 182: 5537-46.
66. Singh R, Paterson Y,. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 2007; 56: 927-38. (Pubitemid 46723584)
67. Sewell DA, Pan ZK, Paterson Y,. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008; 26: 5315-20.
68. Maciag PC, Radulovic S, Rothman J,. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27: 3975-83.
69. Kim SH, Castro F, Paterson Y, et al. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 2009; 69: 5860-6.
70. Shahabi V, Seavey MM, Maciag PC, et al. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-over-expressing cancers in human. Cancer Gene Ther 2011; 18: 53-62.
71. Stritzker J, Pilgrim S, Szalay AA, et al. Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 2008; 8: 94.
72. Niculescu-Duvaz D, Niculescu-Duvaz I, Springer CJ,. Design of prodrugs for suicide gene therapy. Methods Mol Med 2004; 90: 161-202.
73. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 918: 302-6.
74. Rainov NG, Kramm CM,. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr Gene Ther 2001; 1: 367-83.
75. Siders WM, Halloran PJ, Fenton RG,. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res 1996; 56: 5638-46. (Pubitemid 26422166)
76. Peter I, Graf C, Dummer R, et al. A novel attenuated replication- competent adenovirus for melanoma therapy. Gene Ther 2003; 10: 530-9. (Pubitemid 36432604)
77. Schoensiegel F, Paschen A, Sieger S, et al. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther 2004; 11: 408-18. (Pubitemid 38747372)
78. Luu RA, Gurnani K, Dudani R, et al. Delayed expansion and contraction of CD8+ T cell response during infection with virulent Salmonella typhimurium. J Immunol 2006; 177: 1516-25. (Pubitemid 44092485)
79. Kaufmann SH, Raupach B, Finlay BB,. Introduction: microbiology and immunology: lessons learned from Salmonella. Microbes Infect 2001; 3: 1177-81. (Pubitemid 34033752)
80. Stark FC, Sad S, Krishnan L,. Intracellular bacterial vectors that induce CD8 (+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection. Cancer Res 2009; 69: 4327-34.
81. Dunstan SJ, Simmons CP, Strugnell RA,. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect Immun 1998; 66: 732-40. (Pubitemid 28074220)
82. Locht C,. Live bacterial vectors for intranasal delivery of protective antigens. Pharm Sci Technol Today 2000; 3: 121-8. (Pubitemid 30195825)
83. Medina E, Guzman CA,. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001; 19: 1573-80. (Pubitemid 32175714)
84. Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics: a review. Int J Food Microbiol 1998; 44: 93-106.
85. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105. (Pubitemid 39576907)
86. Germann T, Bongartz M, Dlugonska H, et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995; 25: 823-9.
87. Huber VC, Arulanandam BP, Arnaboldi PM, et al. Delivery of IL-12 intranasally leads to reduced IL-12- mediated toxicity. Int Immunopharmacol 2003; 3: 801-9. (Pubitemid 36629446)
88. Drouault S, Corthier G, Ehrlich SD, et al. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 1999; 65: 4881-86.
89. Bermødez-Humarán LG, Cortes-Perez NG, Lefevre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175: 7297-302. (Pubitemid 41713425)
90. Bermødez-Humarán LG, Cortes-Perez NG, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2003; 53: 427-33. (Pubitemid 38586510)
91. Wu C, Yang G, Bermø°dez-Humarán LG, et al. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. Int Immunopharmacol 2006; 6: 610-5.
92. Adel-Patient K, Ah-Leung S, Creminon C, et al. Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005; 35: 539-46. (Pubitemid 40577249)
93. Cortes-Perez NG, Bermø°dez-Humarán LG, Le Loir Y, et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003; 229: 37-42. (Pubitemid 37505000)
94. Liu MA,. Immunologic basis of vaccine vectors. Immunity 2010; 33: 504-15.
95. Letourneau S, Im EJ, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2: e 984.
96. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16: 324-8.
97. Brave A, Ljungberg K, Wahren B, et al. Vaccine delivery methods using viral vectors. Mol Pharm 2007; 4: 18-32.
98. Lasaro MO, Ertl HC,. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17: 1333-9.
99. Kaufman DR, Bivas-Benita M, Simmons NL, et al. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol 2010; 84: 5986-96.
100. Kahl CA, Bonnell J, Hiriyanna S, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 2010; 28: 5691-702.
101. Gabitzsch ES, Xu Y, Yoshida LH, et al. A preliminary and comparative evaluation of a novel Ad5 [E1- E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett 2009; 122: 44-51.
102. Bayer W, Tenbusch M, Lietz R, et al. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol 2009; 84: 1967-76.
103. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 2010; 5: e9015.
104. Killian MS, Roop J, Ng S, et al. CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol 2009; 29: 311-8.
105. Parato KA, Senger D, Forsyth PA, et al. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-76. (Pubitemid 41766784)
106. Lech PJ, Russell SJ,. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines 2010; 9: 1275-1302.
107. Laabs EM, Wu W, Mendez S,. Vaccination with live Leishmania major and CpG DNA promotes IL-2 production by dermal dendritic cells and NK cell activation. Clin Vaccine Immunol 2009; 16: 1601-6.
108. Basile G, Peticca M,. Recombinant protein expression in Leishmania tarentolae. Mol Biotechnol 2009; 43: 273-8.
109. Barouch DH, McKay PF, Sumida SM, et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003; 77: 8729-35. (Pubitemid 36936084)
110. Seaman MS, Peyerl FW, Jackson SS, et al. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 2004; 78: 206-15. (Pubitemid 37549733)
111. Bolhassani A, Taheri T, Taslimi Y, et al. Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 2011; 127: 637-45.
112. Miblitz A, Mottram JC, Overath P, et al. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol Biochem Parasitol 2000; 107: 251-61. (Pubitemid 30211639)
113. Roy G, Dumas C, Sereno D, et al. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. Infections in macrophages and in animal models. Mol Biochem Parasitol 2000; 110: 195-206.
114. Junqueiraa C, Santosa LI, Galvøo-Filhoa B, et al. Trypanosoma cruzi as an effective cancer antigen delivery vector. PNAS 2011; 108: 19695-19700.
115. Bolhassani A, Mohit E, Rafati S,. Different spectra of therapeutic vaccine development against HPV infections: a review. Hum Vaccin 2009; 5: 671-89.
116. Bolhassani A, Safaiyan S, Rafati S,. Improvement of different vaccine delivery systems for cancer therapy: a review. Mol Cancer 2011; 10: 3.
117. Souders NC, Sewell DA, Pan ZK, et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 2007; 7: 2.
118. Sewell DA, Shahabi V, Gunn GR, et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004; 64: 8821-5. (Pubitemid 39665484)
119. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 2005; 13: 89-98. (Pubitemid 40542541)
120. Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV16. J Immunol 2001; 167: 6471-9. (Pubitemid 33081581)
121. Lin CW, Lee JY, Tsao YP, et al. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 2002; 102: 629-37.
122. Lowry F,. Live Listeria vaccine proves safe against end-stage cervical cancer in human trial. Ob Gyn News 2008;Sect 2.
123. Krul MR, Tijhaar EJ, Kleijne JA, et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996; 43: 44-8. (Pubitemid 26360158)
124. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56: 997-1007. (Pubitemid 46675294)
125. Baez-Astua A, Herraez-Hernandez E, Garbi N, et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol 2005; 79: 12807-17. (Pubitemid 41433200)
126. Brodsky JL,. Post-translational protein translocation: not all hsc70s are created equal. Trends Biochem Sci 1996; 21: 122-6.
127. Cyr DM, Neupert W,. Roles for hsp70 in protein translocation across membranes of organelles. In:, Feige U, Morimoto RI, Yahara I, Polla BS, eds. Stress-inducible cellular responses. Switzerland: Birkhauser, 1996. 25-40.